{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:56:17Z","timestamp":1792007777918,"version":"4.4.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102613","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:06:25Z","timestamp":1752797185000},"page":"102613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Primary sclerosing cholangitis: what is new in the therapeutic landscape"],"prefix":"10.1016","volume":"96","author":[{"given":"Armando","family":"Curto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cristoferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-1998","authenticated-orcid":false,"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102613_bib1","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib2","article-title":"What are the lived healthcare experiences of patients with primary sclerosing cholangitis? A community-based qualitative interview study","volume":"15","author":"Arndtz","year":"2025","journal-title":"BMJ Open [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib3","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.24247","article-title":"Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"53","author":"Molodecky","year":"2011","journal-title":"Hepatology [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib5","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis","volume":"21","author":"De Vries","year":"2015","journal-title":"World J Gastroenterol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib6","first-page":"124","article-title":"Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence","volume":"32","author":"Mertz","year":"2019","journal-title":"Ann Gastroenterol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib7","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib8","unstructured":"Primary Sclerosing Cholangitis;\u00a0Nature Reviews Disease Primers. 2025 11:1 [Internet]. 2025 Mar 13 [cited 2025 Mar 23];11(1):1\u20131. Available from: \u3008https:\/\/www.nature.com\/articles\/s41572\u2013025-00606\u20135\u3009."},{"key":"10.1016\/j.coi.2025.102613_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on sclerosing cholangitis","volume":"77","author":"Chazouilleres","year":"2022","journal-title":"J Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J Gastroenterol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib12","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib13","article-title":"Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis","volume":"14","author":"Hussain","year":"2024","journal-title":"BMJ Open [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib14","first-page":"1","article-title":"Fluctuating biomarkers in primary sclerosing cholangitis: a longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF","volume":"3","author":"Fossdal","year":"2021","journal-title":"JHEP Rep [Internet]"},{"key":"10.1016\/j.coi.2025.102613_sbref14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/liv.15471","article-title":"Disease burden in primary sclerosing cholangitis in the Netherlands: a long-term follow-up study","volume":"43","author":"van Munster","year":"2023","journal-title":"Liver Int [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/HEP.0000000000000506","article-title":"Role of microbiome in autoimmune liver diseases","volume":"80","author":"Schneider","year":"2024","journal-title":"Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib18","doi-asserted-by":"crossref","first-page":"E90","DOI":"10.1093\/ibd\/izz027","article-title":"Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary sclerosing cholangitis","volume":"25","author":"Dao","year":"2019","journal-title":"Inflamm Bowel Dis [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointestin Liver Dis [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10875-012-9801-1","article-title":"Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis","volume":"33","author":"Abarbanel","year":"2013","journal-title":"J Clin Immunol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_sbref20","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.17936","article-title":"Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): a matched analysis from the Paediatric PSC Consortium","volume":"59","author":"Ricciuto","year":"2024","journal-title":"Aliment Pharm Ther [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib22","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis","volume":"68","author":"Tan","year":"2019","journal-title":"Gut [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib23","first-page":"1","article-title":"Outcomes of oral vancomycin therapy in children with atypical ulcerative colitis with or without confirmed primary sclerosing cholangitis: a real-world observational study","volume":"12","author":"R\u00e4is\u00e4nen","year":"2025","journal-title":"BMJ Open Gastroenterol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_sbref24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gutjnl-2021-326500","article-title":"Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC","volume":"72","author":"Awoniyi","year":"2023","journal-title":"Gut [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib26","first-page":"1","article-title":"FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial","volume":"15","author":"Al-Shakhshir","year":"2025","journal-title":"BMJ Open [Internet]"},{"key":"10.1016\/j.coi.2025.102613_sbref26","first-page":"1","article-title":"Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis","volume":"14","author":"Ichikawa","year":"2023","journal-title":"Nat Commun [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib28","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/liv.14815","article-title":"Genetically engineered E. coli Nissle attenuates hyperammonemia and prevents memory impairment in bile-duct ligated rats","volume":"41","author":"Ochoa-Sanchez","year":"2021","journal-title":"Liver Int [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41586-024-07681-w","article-title":"In situ targeted base editing of bacteria in the mouse gut","volume":"632","author":"Br\u00f6del","year":"2024","journal-title":"Nature [Internet]"},{"key":"10.1016\/j.coi.2025.102613_sbref29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2023.05.038","article-title":"Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation","volume":"79","author":"Braadland","year":"2023","journal-title":"J Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/apt.17256","article-title":"A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis","volume":"57","author":"Liwinski","year":"2023","journal-title":"Aliment Pharm Ther"},{"key":"10.1016\/j.coi.2025.102613_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib33","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1074\/jbc.M110.164970","article-title":"Identification and functional characterization of TMEM16A, a Ca2+-activated Cl\u2212 channel activated by extracellular nucleotides, in biliary epithelium","volume":"286","author":"Dutta","year":"2011","journal-title":"J Biol Chem [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib34","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"J Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hep.20370","article-title":"Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis","volume":"40","author":"Rost","year":"2004","journal-title":"Hepatology [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/apt.12581","article-title":"Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"39","author":"Karlsen","year":"2014","journal-title":"Aliment Pharm Ther [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib37","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib39","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1016\/S0168-8278(25)00310-1","article-title":"LBO-001 Norucholic acid for the treatment of primary sclerosing cholangitis: 96-week analysis of a pivotal phase 3 trial","volume":"82","author":"Trauner","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102613_bib40","first-page":"1","article-title":"PPAR agonists for the treatment of primary biliary cholangitis: old and new tales","volume":"6","author":"Colapietro","year":"2023","journal-title":"J Transl Autoimmun [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib41","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib42","first-page":"1","article-title":"Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial","volume":"10","author":"Hatami","year":"2022","journal-title":"Pharm Res Perspect [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib43","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1016\/S0168-8278(25)00981-X","article-title":"THU-301 Fibrates in primary sclerosing cholangitis: a multicenter retrospective observational study","volume":"82","author":"Cristoferi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102613_bib44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib45","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1016\/S0168-8278(25)00404-0","article-title":"OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial","volume":"82","author":"Levy","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102613_bib46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000450988","article-title":"Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis","volume":"35","author":"Hegade","year":"2017","journal-title":"Dig Dis [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474124.2025.2473490","article-title":"Cholestatic liver diseases: modern therapeutics","volume":"19","author":"McNally","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib48","first-page":"1","article-title":"Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: open-label pilot study","volume":"7","author":"Bowlus","year":"2023","journal-title":"Hepatol Commun [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib50","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib51","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","article-title":"Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC","volume":"21","author":"Trauner","year":"2023","journal-title":"Clin Gastroenterol Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib53","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000471874","article-title":"Immunosuppressive agents for the treatment of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"35","author":"Peng","year":"2017","journal-title":"Dig Dis [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib54","first-page":"1","article-title":"Efficacy of biologics in the treatment of primary sclerosing cholangitis associated with inflammatory bowel disease: a systematic review and meta-analysis","volume":"16","author":"Huynh","year":"2024","journal-title":"Cureus [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib55","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0168-8278(24)00606-8","article-title":"LBP-039 Oral alpha-v\/beta-6 and alpha-v\/ beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trial","volume":"80","author":"Trauner","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.coi.2025.102613_bib56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40264-024-01436-2","article-title":"Targeting CCL24 in inflammatory and fibrotic diseases: rationale and results from three CM-101 phase 1 studies","volume":"47","author":"Mor","year":"2024","journal-title":"Drug Saf [Internet]"},{"key":"10.1016\/j.coi.2025.102613_sbref56","first-page":"1","article-title":"The role of CCL24 in primary sclerosing cholangitis: bridging patient serum proteomics to preclinical data","volume":"13","author":"Greenman","year":"2024","journal-title":"Cells [Internet]"},{"key":"10.1016\/j.coi.2025.102613_bib58","unstructured":"Oral Presentation at AASLD. The Liver Meeting\u00ae 2024 Highlights Broad Clinical Activity of Chemomab\u2019s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis [Internet]. [cited 2025 Apr 5]. Available from: \u3008https:\/\/investors.chemomab.com\/2024\u201311-19-Oral-Presentation-at-AASLD-The-Liver-Meeting-R-2024-Highlights-Broad-Clinical-Activity-of-Chemomabs-CM-101-Across-Multiple-Biomarkers-and-Its-Disease-Modifying-Potential-in-Primary-Sclerosing-Cholangitis\u3009."},{"key":"10.1016\/j.coi.2025.102613_bib59","article-title":"Medical treatment of primary sclerosing cholangitis: what have we learned and where are we going?","author":"Karlsen","year":"2024","journal-title":"Hepatology\u00a0[Internet]"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:21:56Z","timestamp":1757337716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":59,"alternative-id":["S0952791525000895"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102613","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary sclerosing cholangitis: what is new in the therapeutic landscape","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102613"}}